Biased Agonism of Endogenous Opioid Peptides at the μ-Opioid Receptor.

Endogenous opioid peptides such as α-neoendorphin, Met-enkephalin-Arg-Phe, and endomorphin-1 exhibit distinct biased agonism profiles at the μ-opioid receptor compared to the synthetic agonist DAMGO, indicating natural ligand-specific signaling biases.

The study used a common cellular system to measure multiple signaling pathways activated by endogenous opioid peptides and the synthetic agonist DAMGO. Techniques included assays for G protein activation, cAMP inhibition, ERK1/2 phosphorylation, β-arrestin recruitment, and receptor trafficking, combined with a novel analytical method to quantify biased agonism.

Understanding natural biased agonism at the μ-opioid receptor can guide the design of new opioid drugs that target specific signaling pathways, potentially improving pain management and reducing adverse effects.

The study was conducted in vitro using a single cellular background, so it remains to be confirmed whether these biased signaling profiles translate to different physiological effects in living organisms.